NASDAQMaterialsChemicalsSnapshot 2026-07-31
Reading ORGN? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
The reason to own it still holds.
View ThesisRevenue is contracting — down about 53% over the past year.
View GrowthManagement screens weak on capital allocation, margins, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 3% on a typical day and fell roughly 97% in its worst 12-month stretch.
View RiskORGN's growth depends on reversing its recent weak performance and raising guidance. Revenue has been low, and the last quarter showed a significant miss. It trades at 0.4× price-to-sales, while the peer median is 1.5×. This suggests the price reflects modest growth expectations. A specific risk is the high chance of another miss, with an 81% probability. Peer multiples imply a price about 76% above where it trades; this read is provisional.
Trailing returns as of 2026-07-23. ORGN is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Diversified Chemicals — fair value, gap to price, and forward P/E.
Threatens: Implement organizational realignment
Closures may hinder organizational realignment efforts.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-23. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
